The European Commission and European Medicines Agency (EMA) have published a Q&A document (the EMA Q&A) concerning the legal consequences for marketing authorisation holders (MAHs) of centrally authorised medicines if the UK becomes a ‘third country’ after Brexit. The EMA
Brexit
The UK Government’s Brexit White Paper and its impact on the life sciences sector
Posted on
On February 2, 2017, the Government published a White Paper on its plan for exiting and achieving a new partnership with the EU. The White Paper expands upon Prime Minister Theresa May’s speech on January 17, 2017. We have previously…
The UK Government’s Brexit plan and its implications for life sciences
Posted on
On January 17, 2017, Prime Minister Theresa May delivered her much anticipated speech on the UK Government’s plan for exiting the EU.
Continued membership of the EU’s single market and full membership of the customs union have both been explicitly…